During the first wave of the Covid-19 pandemic, cities were in general affected worse than smaller conurbations or rural areas. Yet in Italy, Rome was relatively spared while the villages of Lombardy experienced very high rates of sickness and death. Then again, one Lombard village Ferrara Erbognone stood out for not recording a single case of Covid-19 at the height of the wave. Nobody knows why.
The puzzle is not just Italian. From the beginning, Covid-19 struck unevenly across the globe, and scientists have been trying to understand the reasons. Why are some populations or sectors of a population more vulnerable than others? Or to turn the question around, why are some groups relatively protected?
In the Observer last weekend, neuroscientist and Covid-19 modeller Karl Friston of University College London suggested on the basis of his comparison of German and British data that the relatively low fatality rates recorded in Germany were due to unknown protective factors at play. This is like dark matter in the universe: we cant see it, but we know it must be there to account for what we can see, he said.
While this is a novel view most experts praise Germanys lockdown and systematic testing regime others are working hard to identify factors which are modulating the spread of Covid-19 and in doing so could explain other puzzles such as why Japan seems to have avoided a lethal first wave despite its relatively old population and lacklustre public health response, or why Denmark, Austria and the Czech Republic have reported no surge in cases despite their early easing of lockdown measures. That could shape how governments manage the risks of a second wave.
One thing seems clear: there are many reasons why one population is more protected than another. Theoretical epidemiologist Sunetra Gupta of the University of Oxford thinks that a key one is immunity that was built up prior to this pandemic. Its been my hunch for a very long time that there is a lot of cross-protection from severe disease and death conferred by other circulating, related bugs, she says. Though that cross-protection may not protect a person from infection in the first place, it could ensure they only experience relatively mild symptoms.
Guptas hunch has remained just that, because of the lack of data on immunity to Covid-19. Antibody testing, as we know, was slow to get going and unreliable to begin with, and the results to date suggest that the proportions of populations carrying antibodies to the Covid-19 virus are often in single or low-double digits. New, more sensitive antibody tests that have become available in recent weeks could soon provide a much more accurate picture if deployed widely enough, but there are already hints that the results to date may be underestimates.
First there was evidence based on diagnostic testing of postmortem samples from patients who died in December that the virus was circulating in western countries notably France and the US about a month earlier than was initially thought. New research shows that another component of the human immune response T cells, which help orchestrate the antibody response show memory for coronavirus infection when exposed to Sars-CoV-2, the virus that causes Covid-19.
In a paper published in Cell on 14 May, researchers at the La Jolla Institute for Immunology in California reported that T cells in blood drawn from people between 2015 and 2018 recognised and reacted to fragments of the Sars-CoV-2 virus. These people could not have possibly seen Sars-CoV-2, says one of the papers senior authors, Alessandro Sette. The most reasonable hypothesis is that this reactivity is really cross-reactivity with the cousins of Sars-CoV-2 the common cold coronaviruses which circulate very broadly and generally give rather mild disease.
The finding supported an earlier one from a group at the Charit hospital in Berlin, detecting T cell reactivity to proteins in the Sars-CoV-2 virus in 83% of Covid-19 patients but also in 34% of healthy volunteers who had tested negative for the virus itself.
David Heymann, an epidemiologist at the London School of Hygiene and Tropical Medicine who advises the World Health Organization on Covid-19, says these results are important, but cautions that cross-reactivity doesnt necessarily translate into immunity. To determine whether it does would involve following a large number of people who show such cross-reactivity to see if they are protected, if not from infection with Covid-19, then at least from severe forms of the disease.
It is, however, a reasonable hypothesis that exposure to other coronaviruses could confer protection, Sette says. Weve seen it before, for example with the 2009 H1N1 flu. Older people fared well compared to other age groups in that pandemic, he says, probably because their immune systems had been primed by exposure to similar flu strains from decades before. That could be the reason the 2009 pandemic was less lethal than other flu pandemics in history, killing an estimated 200,000 people globally.
If exposure to other coronaviruses does protect against Covid-19, Gupta says, then variability in that exposure could explain much of the difference in fatality rates between countries or regions. Exposure to the related virus that caused the epidemic of severe acute respiratory syndrome (Sars) in 2002-4 might have afforded some protection to east Asians against Covid-19, for example.
In late March, Guptas group published a paper that drew attention because it generated very different forecasts from those of epidemiologist Neil Ferguson of Imperial College London and his colleagues to whom the UK government was listening most closely. The Oxford group suggested that up to half of the UK population could already have been infected by Sars-CoV-2, meaning the infection fatality rate (IFR) the proportion of infected people who went on to die was much lower than Fergusons group was indicating, and the disease was therefore less dangerous. Neither group had much data at that point, and Gupta says that her intention was to highlight that, in the absence of data, a wide range of scenarios should be considered.
Two months on, she stands by her model, but wishes that she had made its implications clearer. The truth is that the IFR is not a hardwired property of the virus or of our interaction with the virus, she says. Its the vulnerable fraction [of the population] that is determining the average overall risk of dying. Once an elderly care home is infiltrated by the virus, for example, the virus spreads rapidly through it and is often lethal, pushing up the IFR. This means it is critical to understand why some people are resistant and others are not, so that those who are vulnerable can be protected.
We know some of those vulnerability factors. Age is the most obvious one. Unlike with the 2009 flu, elderly people are particularly vulnerable to Covid-19 a fact that might reflect the history of exposure to coronaviruses of different age cohorts. Comorbidity is another, and a third is being male. According to Garima Sharma of Johns Hopkins University School of Medicine in Baltimore, who with colleagues recently published a paper on sex differences in Covid-19 mortality, women are protected by virtue of having a backup X chromosome. X chromosomes contain a high density of immune-related genes, so women generally mount stronger immune responses, she says.
Socioeconomic status, climate, culture and genetic makeup could also shape vulnerability, as could certain childhood vaccines and vitamin D levels. And all of these factors can vary between countries. The Japanese might have been afforded some protection, for example, by their custom of bowing rather than shaking hands. And though most of the disparity between the sexes is down to biology, Sharma says some of it is due to social and behavioural factors, with women being more likely to wash their hands and seek preventive care.
It is also becoming clear that protecting the vulnerable has made a big difference to outcomes so far. Italy and Germany, for example, have similar proportions of over-65-year-olds just over 20% of the population in both cases and yet the two have reported strikingly different fatality rates. The case fatality rate (CFR) the proportion of the sick who go on to die is less informative but easier to measure than the IFR, because sick people are more visible than merely infected ones, and as at 26 May the CFR in Italy was about 14%, compared to 5% in Germany.
Italy is more densely populated than Germany, and Italian homes tend to be smaller than German ones. Many Italians in their 20s and 30s live at home with their extended families, which meant that transmission to the elderly was high and, when critical care units were overwhelmed, so were deaths. This is rarer in Germany, where many elderly care homes also enacted a strict isolation regime. In Germany, says Heymann, they did a better job in keeping the elderly protected. Some estimates suggest that only 20% of German Covid-19 cases were over 60, as compared to more than 90% in Italy.
The UK, which has recorded the second highest death rate from Covid-19 after Spain, has not looked after its elderly so well deciding at one point to discharge patients from hospitals back to care homes without testing them for the disease. The governments advice to 1.5 million UK citizens with underlying health conditions to self-isolate for three months from late March may have helped protect those people, but for Gupta the UKs high death rate reflects a deeper problem years of erosion of community support services that provided pastoral care. There is just not enough investment in the NHS and in that GP or other frontline individual who advises the vulnerable person, she says.
Holding to her hunch, she believes that lockdown was an overreaction and that frontline care and protection of the vulnerable which should have been a priority from the beginning should be prioritised now. She also thinks that the worst is behind us, and that while subsequent waves cant be ruled out, they will probably be less bad than what we have experienced so far. The disease will settle into an endemic equilibrium, in her view, perhaps returning each winter like a seasonal flu.
Fristons models also suggest that immunity in the population is higher than data indicates, but for him its not clear how long that immunity will last and he argues that test-and-trace protocols should be put in place now, ahead of any possible second wave that might erupt once that immunity drops off. Heymann remains wary of models, which he says have too often been mistaken for reality in this pandemic, and he awaits more data: I dont think anybody can predict the destiny of this virus at this point in time, he says.
Continue reading here:
Are we underestimating how many people are resistant to Covid-19? - The Guardian
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]
- Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis - News-Medical.Net - December 22nd, 2023 [December 22nd, 2023]
- Physician and Patient (Un)Wellness in Allergy and Immunology During COVID-19 and Beyond: Lessons for the Future - Physician's Weekly - December 22nd, 2023 [December 22nd, 2023]
- Researchers Identify Why Some Cancers Do Not Respond to Immunotherapy - NYU Langone Health - December 22nd, 2023 [December 22nd, 2023]
- MU's Haval Shirwan recognized for achievements in immunology - Columbia Daily Tribune - December 22nd, 2023 [December 22nd, 2023]
- Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium - Weill Cornell Medicine Newsroom - December 14th, 2023 [December 14th, 2023]
- Annals of Allergy, Asthma and Immunology Examines Effects of Climate Change on Allergic Conditions - Newswise - December 14th, 2023 [December 14th, 2023]
- British Society for Immunology response to the NHS vaccination strategy - British Society for Immunology | - December 14th, 2023 [December 14th, 2023]
- NYU Langone Health in the NewsFriday, December 8, 2023 - NYU Langone Health - December 14th, 2023 [December 14th, 2023]
- Arturo Casadevall Named Distinguished Fellow by the American Association of Immunologists - Johns Hopkins Bloomberg School of Public Health - December 14th, 2023 [December 14th, 2023]
- ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scien - PharmiWeb.com - December 14th, 2023 [December 14th, 2023]
- Ishares Genomics Immunology And Healthcare Etf ($IDNA) Proactive Strategies - Stock Traders Daily - December 14th, 2023 [December 14th, 2023]
- Medical Breakthroughs Fueling Infection Prevention Market: Immunology and Modern Medicine Advancements to ... - PR Newswire - December 14th, 2023 [December 14th, 2023]
- Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided the detection of the immune ... - EurekAlert - December 14th, 2023 [December 14th, 2023]
- Testing Cancer Immunotherapies on Mice with Human Immune Systems - Mirage News - December 14th, 2023 [December 14th, 2023]
- Georgetown School of Medicine's Department of Immunology Hosts Talk About Therapeutic Vaccine for Autoimmune ... - Georgetown University The Hoya - December 6th, 2023 [December 6th, 2023]
- Long COVID Research Is a Bit of a Mess - Technology Networks - December 6th, 2023 [December 6th, 2023]